PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

Michel Farnier Articles

PCSK9 Clinical trials: What’s new?

PCSK9 Clinical trials: What’s new?

Dr Michel Farnier MD PhD Clinician based at Point Medical, Dijon, France

Posted on 16 July 2015 | Posted by Michel Farnier | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing

ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing

Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with 4-weekly regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…

Posted on 18 March 2015 | Posted by Michel Farnier | Posted in News, 64th Annual Scientific Session of the American College of Cardiology 2015

Play

ODYSSEY FHI FHII

ODYSSEY FHI FHII

Fewer than 80% of familial hypercholesterolaemia (FH) patients achieved an LDL-C level of

Posted on 2 September 2014 | Posted by Michel Farnier | Posted in News, Videos, European Society of Cardiology Congress 2014

PCSK9: From discovery to therapeutic applications

PCSK9: From discovery to therapeutic applications

PUBMED abstract: http://www.ncbi.nlm.nih.gov/pubmed/24373748

Posted on 20 February 2014 | Posted by Michel Farnier | Posted in Article Archive

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved